IP Library Granted Patent US 7,510,850
Granted Patent B2
US 7,510,850 · App. 11/598,148 · Granted Mar 31, 2009

Isolation of the mitotic spindle matrix and its methods of use

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,510,850
App. No.
11/598,148
Granted
Mar 31, 2009
Kind
B2
Abstract

The invention encompasses a purified preparation of the mitotic spindle matrix essential for mitotic spindle assembly, which allows for identifying an agent that modulates a cell division and/or differentiation signaling pathway comprising determining the effect of the agent on spindle formation, MT nucleation, or lamin matrix assembly wherein the change in spindle formation, MT nucleation or lamin matrix assembly.

Claims (13)

1. A method for identifying an agent that modulates a cell division and/or differentiation signaling pathway comprising:

(a) contacting a solid surface linked to an Aurora A protein with a cell lysate or cell extract sample in the presence or absence of said agent;

(b) determining the effect on spindle formation, microtubule nucleation, or lamin-membrane matrix assembly wherein a change in spindle formation, microtubule nucleation or lamin-membrane matrix assembly compared to a control in the absence of the agent indicates an agent capable of modulating a cell division and/or differentiation signaling pathway.

2. The method of claim 1 , wherein the method further comprises the step of adding Ran protein to the sample.

3. The method of claim 1 , wherein the cell lysate or cell extract sample comprises one or more proteins selected from the group consisting of Spindle Assembly Factors, filament proteins and kinesins.

4. The method of claim 3 , wherein the cells are HeLa cells, NIH3T3 cells or embryonic stem cells.

5. The method of claim 3 , wherein the cell extract is Xenopus egg extracts.

6. The method of claim 1 , wherein said solid surface comprises beads or dots.

7. The method of claim 1 , wherein said Aurora A protein is wild-type Aurora A.

8. The method of claim 1 , wherein the method further comprises a second control, wherein the Aurora A protein is not present in the sample.

9. The method of claim 1 , wherein the method further comprises a second control, wherein a known inhibitor of microtubule nucleation, spindle formation or lamin formation is present in the sample.

10. The method of claim 1 , wherein said solid surface is magnetic beads.

11. The method of claim 1 , wherein said solid surface is quantum dots.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 14, 2007
From: HOWARD HUGHES MEDICAL INSTITUTE
To: CARNEGIE INSTITUTION OF WASHINGTON
Reel/Frame 018906/0146 →